Concepedia

Paul A. Reilly

PA

16

Publications

2.8K

Citations

15

H-Index

1989

Active since

Affiliations

Boehringer Ingelheim (United States)(Current)

Boehringer Ingelheim (Germany)

Heidelberg University

McMaster University

Leiden University

Paul A. Reilly is an author at Boehringer Ingelheim (United States) specializing in medicine, thrombosis, and rheumatoid arthritis.

ORCID

Top concepts

Publications per year

1989–2020

16

Publications

16

Idarucizumab for Dabigatran Reversal

Charles V. Pollack, Paul A. Reilly, John W. Eikelboom et al. · New England Journal of Medicine · 2015 · 1.4K citations

Safety and Efficacy of Dabigatran Etexilate vs Dose-Adjusted Warfarin in Patients With Cerebral Venous Thrombosis

José M. Ferro, Jonathan M. Coutinho, Francesco Dentali et al. · JAMA Neurology · 2019 · 288 citations · Full text

Oral bioavailability of dabigatran etexilate (<scp>P</scp>radaxa<sup>®</sup>) after co‐medication with verapamil in healthy subjects

Sebastian Härtter, Regina Sennewald, Gerhard Nehmiz et al. · British Journal of Clinical Pharmacology · 2012 · 161 citations · Full text

Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran

Paul A. Reilly, Richard A. Bernstein, Robert Dubiel et al. · Thrombosis and Haemostasis · 2015 · 153 citations

Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial

Leonardo R. Brandão, Matteo Luciani, Lisa Bomgaars et al. · The Lancet Haematology · 2020 · 134 citations · Full text

, , +8

Rows per page

1–5 of 16